Adopted opinions and previous consultations on applications for authorisation

This page provides further information on the applications for authorisation or review reports, which have undergone consultation. The applications for authorisation are in the opinion development phase until the final opinions of the Committees for Risk Assessment and Socio-economic Analysis have been adopted and sent to the European Commission. Its decision-making process can be followed through the comitology register, where further information is published about the REACH Committee's past and upcoming meetings.

On 1 February 2020, the United Kingdom (UK) withdrew from the EU. The transition period provided by the withdrawal agreement ended on 31 December 2020. As of 1 January 2021, an application for an authorisation submitted by a person established in the UK (except Northern Ireland) is no longer valid in the EU, unless that application has been transferred to a legal entity established in the EU or Northern Ireland before the end of the transition period. Therefore, authorisation applications and decisions in so far as these concern persons established in the UK (except Northern Ireland) are no longer considered valid.

ID	Application type	Name	EC Number	CAS Number	Applicant(s)	Use name	Status
0247-01	Initial	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	Boehringer Ingelheim RCV GmbH & Co KG	Use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated as a detergent in the purification of lipidated OspA protein subsequently used for manufacturing of Lyme disease vaccine candidate.	Opinions adopted
0246-01	Initial	2,2'-dichloro-4,4'-methylenedianiline (MOCA)	202-918-9	101-14-4	Courbis Synthèse Annovi S.r.l.; Dansk Elastomer A/S; Durlast S.r.l.; Pieffe S.r.l.; Policart S.r.l.; R.B.M. Italia S.r.l.; Tecnocaucho S.A.; Tegea S.r.l.; Optibelt Urethane Belting Ltd.; Productos Salinas S.A.; V.M. SPA	Industrial use of 2,2'-Dichloro-4,4'-methylenedianiline (MOCA) in the manufacture of hot cast polyurethane products	Opinions adopted
0245-01	Initial	Chromium trioxide	215-607-8	1333-82-0	NEWFORM S.P.A.	Electroplating of different types of substrates using Chromium Trioxide to achieve functional surfaces with high durability and a bright or matt silvery appearance for sanitary applications	Opinions adopted
0244-02	Initial	Chromium trioxide	215-607-8	1333-82-0	CROMAPLAST S.p.A.	Industrial use of CrO3 in the chrome plating of automotive plastic components	Opinions adopted
0244-01	Initial	Chromium trioxide	215-607-8	1333-82-0	CROMAPLAST S.p.A.	Industrial use of CrO3 in the pre-treatment (etch) in the chrome plating process of automotive plastic components	Opinions adopted
0243-01	Review report	Trichloroethylene	201-167-4	79-01-6	DOMO Caproleuna GmbH	Industrial use as an extraction solvent for the purification of caprolactam from caprolactam oil	Opinions adopted
0242-01	Review report	Trichloroethylene	201-167-4	79-01-6	Microporous GmbH	Trichloroethylene used as extraction solvent in the manufacture of polyethylene separators for lead-acid batteries	Opinions adopted
0241-01	Initial	Chromium trioxide	215-607-8	1333-82-0	Gessi S.p.A. San Marco Rubinetteria S.r.l.	Use of chromium trioxide for electroplating of metal substrates with the purpose of creating a long-lasting high durability surface with bright look for kitchen and bathroom sanitaryware (functional plating with decorative character)	Opinions adopted
0240-01	Initial	4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated	-	-	Alexion Pharma International Operations Unlimited Company	Industrial use of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated for virus inactivation in the manufacture Andexanet alfa for treatment of adult patients treated with a direct factor Xa (FXa) inhibitor when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding	Opinion development
0239-02	Initial	4-Nonylphenol, branched and linear, ethoxylated	-	-	Prionics Lelystad B.V.	Use as component of buffer solutions to produce antigens (Cell extraction, cell lysis, coating of biological antigens onto articles, inactivation of microorganisms that produce targeted antigen and solvent exchange) and in-process and final Quality Control of antigens intended for use as veterinary and human health laboratory reagents in Scientific Research and Development and In Vitro Diagnostic applications	Opinion development

Showing 81 - 90 of 486 results.

Export in:

EU Privacy Disclaimer